Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INO NASDAQ:OM NASDAQ:OSRH NASDAQ:QTI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINOInovio Pharmaceuticals$1.19+3.9%$1.45$1.03▼$2.98$82.29M1.431.57 million shs733,716 shsOMOutset Medical$4.49-5.9%$3.84$3.00▼$21.98$83.20M1.92566,919 shs82,403 shsOSRHOSR$0.53+3.1%$0.51$0.38▼$1.79$17.69M0.865.14 million shs2.02 million shsQTIQT Imaging$6.85+0.8%$6.43$0.65▼$8.50$82.41M0.0134,535 shs2,471 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINOInovio Pharmaceuticals+3.64%-0.87%+0.88%-31.74%-38.71%OMOutset Medical+9.40%+10.42%+18.95%-2.65%-59.51%OSRHOSR-18.61%-30.38%-5.75%-10.50%-62.18%QTIQT Imaging+2.57%+4.14%+3.66%+24.13%+759.49%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINOInovio Pharmaceuticals$1.19+3.9%$1.45$1.03▼$2.98$82.29M1.431.57 million shs733,716 shsOMOutset Medical$4.49-5.9%$3.84$3.00▼$21.98$83.20M1.92566,919 shs82,403 shsOSRHOSR$0.53+3.1%$0.51$0.38▼$1.79$17.69M0.865.14 million shs2.02 million shsQTIQT Imaging$6.85+0.8%$6.43$0.65▼$8.50$82.41M0.0134,535 shs2,471 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINOInovio Pharmaceuticals+3.64%-0.87%+0.88%-31.74%-38.71%OMOutset Medical+9.40%+10.42%+18.95%-2.65%-59.51%OSRHOSR-18.61%-30.38%-5.75%-10.50%-62.18%QTIQT Imaging+2.57%+4.14%+3.66%+24.13%+759.49%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINOInovio Pharmaceuticals 2.38Hold$6.75469.62% UpsideOMOutset Medical 2.60Moderate Buy$10.00122.72% UpsideOSRHOSR 1.00SellN/AN/AQTIQT Imaging 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest OSRH, OM, QTI, and INO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/20/2026QTIQT Imaging Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold3/27/2026OMOutset Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026OSRHOSR Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/13/2026INOInovio Pharmaceuticals OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform2/27/2026QTIQT Imaging Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell2/12/2026OMOutset Medical BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$17.00 ➝ $15.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINOInovio Pharmaceuticals$60K1,371.44N/AN/A$0.36 per share3.29OMOutset Medical$119.48M0.70N/AN/A$6.99 per share0.64OSRHOSR$2.91M6.08N/AN/A$4.95 per share0.11QTIQT Imaging$18.92M4.36N/AN/A$0.54 per share12.68Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINOInovio Pharmaceuticals-$84.95M-$1.68N/AN/AN/AN/A-259.70%-83.46%5/12/2026 (Estimated)OMOutset Medical-$81.65M-$6.79N/AN/AN/A-68.34%-55.65%-28.64%5/7/2026 (Estimated)OSRHOSR-$27.06M-$1.28N/AN/AN/A-619.82%-13.53%-10.17%N/AQTIQT Imaging-$21.08M-$2.19N/A26.33N/A-111.40%N/A-115.44%5/12/2026 (Estimated)Latest OSRH, OM, QTI, and INO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026INOInovio Pharmaceuticals-$0.30N/AN/AN/A$0.33 millionN/A5/12/2026N/AQTIQT Imaging-$0.1350N/AN/AN/A$6.45 millionN/A5/7/2026Q1 2026OMOutset Medical-$0.79N/AN/AN/A$28.90 millionN/A3/12/2026Q4 2025INOInovio Pharmaceuticals-$0.37$0.31+$0.68$0.31$0.33 millionN/A2/18/2026Q4 2025QTIQT ImagingN/A-$0.10N/A-$0.10N/A$8.27 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthINOInovio PharmaceuticalsN/AN/AN/AN/AN/AOMOutset MedicalN/AN/AN/AN/AN/AOSRHOSRN/AN/AN/AN/AN/AQTIQT ImagingN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINOInovio PharmaceuticalsN/A1.401.40OMOutset Medical0.766.675.40OSRHOSRN/A0.160.15QTIQT Imaging0.712.812.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINOInovio Pharmaceuticals26.79%OMOutset MedicalN/AOSRHOSR55.30%QTIQT Imaging24.19%Insider OwnershipCompanyInsider OwnershipINOInovio Pharmaceuticals1.70%OMOutset Medical2.50%OSRHOSR60.60%QTIQT Imaging28.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINOInovio Pharmaceuticals32069.44 million68.26 millionOptionableOMOutset Medical52018.53 million18.07 millionNot OptionableOSRHOSRN/A33.12 million13.05 millionN/AQTIQT ImagingN/A12.04 million8.57 millionN/AOSRH, OM, QTI, and INO HeadlinesRecent News About These CompaniesQT Imaging (QTI) Projected to Post Quarterly Earnings on TuesdayMay 5 at 12:50 PM | marketbeat.comQT Imaging (NASDAQ:QTI) Stock Rating Upgraded by Zacks ResearchApril 22, 2026 | marketbeat.comQT Imaging Debuts the QT Imaging-Olea Viewer for Integrated, Multimodality Breast Imaging Within a Single User InterfaceApril 15, 2026 | businesswire.comQT Imaging Holdings Insider Trading Activity | NASDAQ:QTI | BenzingaApril 8, 2026 | benzinga.comQT Imaging Holdings, Inc. Common Stock (QTI)April 4, 2026 | nasdaq.comQT Imaging CEO Discusses the Importance of Early Breast Cancer Detection at the Shiftmakers’ Panel and GalaApril 2, 2026 | gazettextra.comGQT Imaging CEO Discusses the Importance of Early Breast Cancer Detection at the Shiftmakers' Panel and GalaApril 2, 2026 | businesswire.comQT Imaging Releases Its Next Generation Breast Imaging Reconstruction SoftwareApril 1, 2026 | businesswire.comQT Imaging Holdings Inc (QTI) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ...March 26, 2026 | uk.finance.yahoo.comQT Imaging Reports 2025 Fourth Quarter and Full Year Financial ResultsMarch 25, 2026 | finance.yahoo.comQT Imaging Receives UAE Regulatory ClearanceMarch 24, 2026 | businesswire.comQT Imaging to Hold 2025 Fourth Quarter and Full Year Conference Call on March 25, 2026March 18, 2026 | businesswire.comQTI Share News TodayMarch 11, 2026 | uk.investing.comQT Imaging Receives FDA Clearance for Its Breast Acoustic CT Scanner Enhanced Configuration to Improve Posterior Breast Imaging CoverageMarch 10, 2026 | finance.yahoo.comQT Imaging Names Renowned Breast Cancer Researcher Dr. Mary Yamashita as Medical AdvisorMarch 4, 2026 | tmcnet.comQT Imaging Achieves Major Reimbursement Milestone with AMA Category III CPT Code for 3D Breast Ultrasound TomographyFebruary 23, 2026 | businesswire.comQT Imaging Reports Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial ResultsFebruary 18, 2026 | finance.yahoo.comQT Imaging Files Audited 2024-2023 Financial StatementsFebruary 6, 2026 | tipranks.comQT Imaging Announces Presentation at SPIE Medical Imaging 2026February 3, 2026 | tmcnet.comQT Imaging & Olea Medical partner to enhance cloud imaging platformJanuary 30, 2026 | msn.comQT Imaging Announces Uplisting to NasdaqJanuary 27, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 20263 Discounted Stocks With Strong Rebound PotentialBy Chris Markoch | April 6, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 2026NVIDIA's Quantum Computing Play Just Sent IonQ and Rigetti Flying By Jeffrey Neal Johnson | April 15, 2026OSRH, OM, QTI, and INO Company DescriptionsInovio Pharmaceuticals NASDAQ:INO$1.18 +0.05 (+3.95%) As of 12:01 PM Eastern This is a fair market value price provided by Massive. Learn more.Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.Outset Medical NASDAQ:OM$4.49 -0.28 (-5.87%) As of 12:00 PM Eastern This is a fair market value price provided by Massive. Learn more.Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also provides Tablo Data Ecosystem, including TabloHub, a customer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.OSR NASDAQ:OSRH$0.53 +0.02 (+3.07%) As of 12:00 PM Eastern This is a fair market value price provided by Massive. Learn more.OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D "platform technologies" versus "assets only" companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.QT Imaging NASDAQ:QTI$6.84 +0.06 (+0.81%) As of 11:21 AM Eastern This is a fair market value price provided by Massive. Learn more.QT Imaging Holdings, Inc. engages in the research, development, and commercialization of body imaging systems for detection, diagnosis, monitoring, and treatment of diseases. The company offers QT Ultrasound Breast Scanner, an ultrasonic imaging system that provides reflection-mode and transmission-mode images of a patient's breast. QT Imaging Holdings, Inc. was founded in 2011 and is based in Novato, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
